
Vandria is a clinical-stage biotech developing small molecules against a novel target, with VNA-318 targeting early-stage CNS and neurodegenerative patients.
vandria.comCrawled Nov 2, 2026
Vandria reports Phase 1 trial results indicating its experimental drug **VNA-318** demonstrates a functional mechanism in humans. The multiple ascending dose study suggests the therapy may help meet unmet medical needs in patients with neurodegenerative diseases. Vandria specializes in first-in-class treatments targeting age-related conditions.
Vandria presents safety and target engagement results for its Alzheimer’s drug candidate **VNA-318** in phase 1 trials. The findings, shared at the **Clinical Trials on Alzheimer’s Disease (CTAD) meeting**, indicate the treatment meets early efficacy benchmarks without significant adverse effects. Researchers emphasize the candidate’s potential to address unmet needs in Alzheimer’s therapy development.
Vandria’s experimental drug **VNA-318** demonstrates positive Phase 1 target engagement in Alzheimer’s disease trials. The oral, brain-penetrant small molecule modulates a novel biological pathway to reduce neuroinflammation and enhance mitochondrial function. These findings support Vandria’s continued development of VNA-318 as a potential treatment for Alzheimer’s.
Vandria, a Lausanne-based biotech company, presents early human trial results for its Alzheimer’s drug candidate **VNA-318**. The small molecule targets mitochondrial health, aligning with emerging research on neurodegenerative disease mechanisms. Data was shared ahead of the Clinical Trials on Alzheimer’s Disease (CTAD) conference.
Vandria raises $30.7 million in its Series A funding round. The Vaud-based biotech company adds institutional investors Hevolution Foundation and Dolby Family Ventures, alongside its founding investor ND Capital. This marks the second closing of the Series A, finalizing the total raised to date.
Vandria secures **$30.7M (CHF 28.3M)** in its **Series A-2** funding round, led by **Hevolution Foundation** and **Dolby Family Ventures**, to advance its **mitophagy-inducing CNS drug VNA-318** into clinical development. The compound targets cognitive function improvement through a **dual mechanism**, combining immediate symptom relief with long-term disease modification. This funding supports Vandria’s progression toward **clinical trials** for central nervous system disorders.
Vandria secures **$20.6 million (CHF18 million)** in Series A funding, led by **ND Capital**, to advance its **central nervous system (CNS) clinical program** and **mitochondrial therapeutics platform**. The financing supports drug development targeting neurological and metabolic disorders. The company operates in stealth mode, focusing on novel treatments for mitochondrial-related diseases.